Findings

What do systematic reviews say?

9 questions · 9 findings · 3 reviews · Headline outcomes only

No studies found 1 · 11.1%GRADE not reported 0 · 0%Very low 1 · 11.1%Low 4 · 44.4%Moderate 2 · 22.2%High 1 · 11.1%

QoL · recurrent platinum‐resistant EOC

Chemotherapy with TKI showed no clear difference in quality of life (QoL) compared with chemotherapy alone (low certainty).

1 finding from 1 review

Angiogenesis inhibitors for the treatment of epithelial ovarian cancer 2023 · Cochrane Headline outcomes only
no estimate extracted
3 studies · 164 participants
Low

QoL · platinum‐sensitive recurrent EOC

1 finding from 1 review

Angiogenesis inhibitors for the treatment of epithelial ovarian cancer 2023 · Cochrane Headline outcomes only
no estimate extracted
1 study · 146 participants
Low

QoL · recurrent EOC

1 finding from 1 review

Angiogenesis inhibitors for the treatment of epithelial ovarian cancer 2023 · Cochrane Headline outcomes only
no estimate extracted
1 study · 315 participants
Low

QoL · newly‐diagnosed EOC

1 finding from 1 review

Angiogenesis inhibitors for the treatment of epithelial ovarian cancer 2023 · Cochrane Headline outcomes only
no estimate extracted
1 study · 1340 participants
Moderate

QoL · platinum‐sensitive recurrent EOC

1 finding from 1 review

Angiogenesis inhibitors for the treatment of epithelial ovarian cancer 2023 · Cochrane Headline outcomes only
no estimate extracted
1 study · 486 participants
Low

QoL · newly‐diagnosed EOC

1 finding from 1 review

Angiogenesis inhibitors for the treatment of epithelial ovarian cancer 2023 · Cochrane Headline outcomes only
no estimate extracted
1 study · 890 participants
High

QoL · newly‐diagnosed EOC

1 finding from 1 review

Poly(ADP‐ribose) polymerase (PARP) inhibitors for the treatment of ovarian cancer 2022 · Cochrane Headline outcomes only
no estimate extracted
1 study · 744 participants
Moderate

QoL · newly‐diagnosed EOC

The review found no eligible studies for this question.

1 finding from 1 review

Angiogenesis inhibitors for the treatment of epithelial ovarian cancer 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Health status and quality of life · people with advanced gastric cancer

1 finding from 1 review

Molecular‐targeted first‐line therapy for advanced gastric cancer 2016 · Cochrane Headline outcomes only
no estimate extracted
1 study · 53 participants
Very low